TACE联合利卡汀治疗对肝癌患者病理指标及CTCs检出数的影响

发布时间：2019-04-03 16:37

【摘要】：目的探讨经导管肝动脉化疗栓塞术(TACE)联合利卡汀治疗对肝癌患者病理指标及循环肿瘤细胞(CTCs)检出数的影响。方法选取2014年1月-2016年6月在沭阳中山医院介入科接受治疗的120例原发性肝癌患者作为该研究对象。根据患者治疗意愿将其分为对照组和实验组,其中对照组52例,仅给予经导管肝动脉化疗栓塞术治疗,实验组68例,在对照组治疗基础上联合利卡汀治疗。比较两组患者治疗前后肿块大小、甲胎蛋白(AFP)水平、血象、肝功能、CTCs以及CD147不同分子表型患者。结果治疗后两组患者肿瘤大小相比差异无统计学意义(P0.05);治疗后,两组AFP水平比较,差异有统计学意义(P0.05),实验组低于对照组;治疗后,两组白细胞计数和丙氨酸转氨酶比较,差异有统计学意义(P0.05),白细胞计数实验组低于对照组,丙氨酸转氨酶实验组高于对照组;治疗后两组CTCs检出数目比较,差异有统计学意义(P0.05),均降低,且实验组低于对照组;实验组CD147 2种表型患者治疗前后CTCs数目变化值间比较,差异有统计学意义(P0.05);对照组CD147 2种表型患者治疗前后CTCs数目变化值间比较,差异无统计学意义(P0.05);两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论利卡汀联合TACE治疗肝癌,临床效果优于单纯TACE治疗,此外,利卡汀对于CD147~+肝癌患者治疗效果优于CD147~-患者。
[Abstract]:Objective To study the effect of transcatheter hepatic arterial chemoembolization (TACE) on the pathological index and the number of circulating tumor cells (CTCs) in patients with liver cancer. Methods 120 patients with primary liver cancer who received the treatment in the interventional department of Zhongshan Hospital from January 2014 to June 2016 were selected as the subject of the study. The control group and the experimental group were divided into the control group and the experimental group according to the patient's treatment intention. The size of mass, alpha-fetoprotein (AFP), blood image, liver function, CTCs and CD147 were compared between the two groups. Results There was no significant difference in the tumor size of the two groups after the treatment (P0.05). After the treatment, the levels of AFP in the two groups were statistically significant (P0.05), and the experimental group was lower than that of the control group. After the treatment, the two groups of white blood cell count and the alanine aminotransferase were compared. The difference was significant (P0.05). The experimental group of the white blood cell count was lower than that of the control group, and the experimental group of the alanine aminotransferase was higher than that of the control group. The number of CTCs in the two groups was significantly lower than that of the control group (P0.05), and the experimental group was lower than that of the control group. There was no significant difference between the changes in the number of CTCs before and after the treatment of CD147 in the experimental group (P <0.05), and the difference in the number of CTCs before and after the treatment of CD147 in the control group was not statistically significant (P0.05). The incidence of adverse reactions in the two groups was compared. The difference was not significant (P0.05). Conclusion The clinical effect of Ligabat combined with TACE in the treatment of liver cancer is superior to that of single TACE. In addition, the therapeutic effect of liqin on the patients with CD147 ~ + liver cancer is better than that of CD147 ~-patients.
【作者单位】：江苏省沭阳中山医院普外科;上海东方肝胆外科医院胆道一科;
【基金】：上海市科学技术委员会科技发展基金(No:12211967700)
【分类号】：R735.7

【相似文献】